-

EUROAPI: Availability of 2023 Half-Year Financial Report

PARIS--(BUSINESS WIRE)--Regulatory News:

EUROAPI (Paris:EAPI) posted today its 2023 Condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2023. This document is available for consultation and downloading on EUROAPI’s website: https://www.euroapi.com/en/investors/regulatory-information/financial-reports.

This report includes notably the 2023 half-year activity report, the summary consolidated financial statements on 30 June 2023, and the Statutory Auditors’ review report on the 2023 half-year results.

Financial Calendar

  • February 29th, 2024 (before market opening): Full Year 2023 results
  • May 22nd, 2024: Annual Shareholder General Meeting
  • July 31st, 2024 (before market opening): H1 2024 Results

About EUROAPI

EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities.

Taking action for health by enabling access to essential therapies inspires our 3,450 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext Paris; ISIN: FR0014008VX5; ticker: EAPI). Find out more at www.euroapi.com and follow us on LinkedIn.

Contacts

Media Relations contact:
Laurence Bollack
Tel.: +33 (0)6 81 86 80 19
mr@euroapi.com

Investor Relations contact:
Sophie Palliez-Capian
Tel.: +33 (0)6 87 89 33 51
Sophie.palliez@euroapi.com

EUROAPI

BOURSE:EAPI
Release Versions
EnglishFrench

Contacts

Media Relations contact:
Laurence Bollack
Tel.: +33 (0)6 81 86 80 19
mr@euroapi.com

Investor Relations contact:
Sophie Palliez-Capian
Tel.: +33 (0)6 87 89 33 51
Sophie.palliez@euroapi.com

More News From EUROAPI

EUROAPI Enhances Its CDMO Capabilities Through a Pivotal Collaboration With SpiroChem, a Leading Contract Research Organization (CRO)

PARIS & BASEL, Switzerland--(BUSINESS WIRE)--Regulatory News: EUROAPI (Paris:EAPI) announced today that it has initiated a pivotal collaboration with SpiroChem, a leading Contract Research Organization (CRO) with best-in-class status in the field of early Chemical Process R&D (route scouting). SpiroChem is headquartered in Basel, Switzerland. SpiroChem and EUROAPI are joining forces to offer their customers a consolidated CRO-CDMO solution, ensuring that industrialization constraints for sm...

EUROAPI Strengthens its Executive Committee with the Appointment of Ludwig de Mot as Executive Vice President - Chief Transformation Officer

PARIS--(BUSINESS WIRE)--Regulatory News: EUROAPI (Paris:EAPI) today announced the appointment of Ludwig de Mot as Executive Vice President (EVP) - Chief Transformation Officer. Ludwig de Mot’s roadmap will focus on accelerating the company’s transformation, including the completion and execution of the Strategic Review initiated by EUROAPI’s Board of Directors in Q4 2023. This comprehensive review spans the entire spectrum of EUROAPI as an organization, including the assessment of its current p...

EUROAPI Appoints New Executive Committee Members

PARIS--(BUSINESS WIRE)--Regulatory News: EUROAPI (Paris:EAPI) today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization, focusing on reinforcing robustness and compliance on the entire end-to-end supply chain whilst bringing relevant innova...
Back to Newsroom